Sophie Cousin

Mature tertiary lymphoid structures predict immune checkpoint inhibitor efficacy in solid tumors independently of PD-L1 expression

Lucile Vanhersecke, Maxime Brunet, Jean‐Philippe Guégan et al. · Nature Cancer · 2021 · 569 citations · Full text

Life Sciences, Immunology, Oncology +17

Use of PD-1 Targeting, Macrophage Infiltration, and IDO Pathway Activation in Sarcomas

Maud Toulmonde, Nicolas Penel, Julien Adam et al. · JAMA Oncology · 2017 · 394 citations · Full text

Medicine, Immunology, Oncology +17

Outcome of Patients with Non–Small Cell Lung Cancer and Brain Metastases Treated with Checkpoint Inhibitors

Lizza Hendriks, Clémence Henon, Édouard Auclin et al. · Journal of Thoracic Oncology · 2019 · 242 citations · Full text

Medicine, Oncology, Pharmacotherapy +14

Patterns of care and outcomes of patients with METAstatic soft tissue SARComa in a real-life setting: the METASARC observational study

M. Savina, Axel Le Cesne, Jean‐Yves Blay et al. · BMC Medicine · 2017 · 212 citations · Full text

Medicine, Clinical Sciences, Oncology +13

Phase 1 Study of Molibresib (GSK525762), a Bromodomain and Extra-Terminal Domain Protein Inhibitor, in NUT Carcinoma and Other Solid Tumors

Sarina A. Piha‐Paul, Christine L. Hann, Christopher A. French et al. · JNCI Cancer Spectrum · 2019 · 207 citations · Full text

Medicine, Oncology, Pharmacology +17